^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Hairy Cell Leukemia
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Blood
    Title:

    Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

    Excerpt:
    ...1 pt developed acquired resistance to vemurafenib with KRAS mutation….
    DOI:
    https://doi.org/10.1182/blood-2018-99-119949